This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

Welcome to the GIOTRIF® website for international healthcare professionals outside the United States of America and the United Kingdom

This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information on Giotrif®.

While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that the registration status and approved product labels of Giotrif® may not be the same in different countries.

Information on this website is derived from the Summary of Product Characteristics (SPC) for Giotrif® in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.

By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and have read and understood this disclaimer.

leave website
Go to US Gilotrif® website for healthcare professionals in the US
Go to UK prescribing information website for healthcare professionals in the UK
  1. 1st-line PFS benefit versus chemotherapy
  2. OS benefit in del19 versus chemotherapy 
  3. Irreversible ErbB family blocker with consistent efficacy
  4. Efficacy benefit versus erlotinib in SqCC 
  5. Effective in many uncommon mutations
  6. Positive effect on tumour symptoms and QoL
  7. Dose modification without compromising efficacy
  8. Efficacy benefit versus gefitinib 
  9. Efficacy in brain metastases patients
  10. Allows for subsequent treatment options

Find your reasons to use GIOTRIF®

Watch Nicolas Girard talk about treatment sequencing!

Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?

Nicolas Girard, Future Oncology, 2018

 

Download the publication!

GIOTRIF® (afatinib) has a manageable AE profile with dose modification proven to reduce AEs without compromising efficacy

GIOTRIF® (afatinib) has a manageable AE profile with dose modification proven to reduce AEs without compromising efficacy

*A grouped term.

  • The most common AEs with GIOTRIF® (afatinib) were generally manageable through supportive care1,2
  • Treatment-related discontinuation due to any AE was low1,2
  • GIOTRIF® (afatinib) dose modification was effective at reducing AE incidence and severity3,4
  • GIOTRIF® (afatinib) dose modification does not affect treatment efficacy3,4

*A grouped term.

View more

Oxford University Press: Does dose adjustment affect safety and efficacy of afatinib for EGFR M+ NSCLC?

 
X-Lung 7 practice changing? 

Is LUX-Lung 7 practice changing? 

See what Dr. Lester and Dr. Shah think
Case study: See how head-to-head data may help George in squamous NSCLC

Case study: See how head-to-head data may help George in squamous NSCLC

Disclaimer

You're now leaving our website...

Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.

Do you want to continue?

Continue
Request contact
from Boehringer Ingelheim

References

  1. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.
  2. Park K et al. Lancet Oncol. 2016;17(5):577-589.
  3. Hirsch V et al. Poster #369 presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 3-7 June 2016.
  4. Yang JCH et al. Ann Oncol. 2016;27(11):2103-2110.

Report an adverse event

If you wish to report an adverse event (AE) after treatment with one of our products, please select your site from the link below. This will allow reporting of AEs in line with the reporting procedure effective in your country for reporting.

Boehringer Ingelheim local websites
Back to top

© 1999 - 2019 Boehringer Ingelheim International GmbH. All rights reserved.